blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3500296

EP3500296 - COMBINATION THERAPY OF BACE-1 INHIBITOR AND ANTI-N3PGLU ABETA ANTIBODY [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  02.07.2021
Database last updated on 26.06.2024
FormerRequest for examination was made
Status updated on  27.05.2019
FormerThe international publication has been made
Status updated on  24.02.2018
Formerunknown
Status updated on  04.09.2017
Most recent event   Tooltip02.07.2021Application deemed to be withdrawnpublished on 04.08.2021  [2021/31]
Applicant(s)For all designated states
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
[2019/26]
Inventor(s)01 / MERGOTT, Dustin James
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis Indiana 46206-6288 / US
02 / WILLIS, Brian Andrew
c/o Eli Lilly and Company
P.O. Box 6288
Indianapolis Indiana 46206-6288 / US
 [2019/26]
Representative(s)Bassinder, Emma Marie
Eli Lilly and Company Limited
8 Arlington Square West Downshire Way
Bracknell, Berkshire RG12 1PU / GB
[N/P]
Former [2019/26]Bassinder, Emma Marie
Eli Lilly and Company Limited
European Patent Operations
Erl Wood Manor
Sunninghill Road
Windlesham, Surrey GU20 6PH / GB
Application number, filing date17757632.911.08.2017
[2019/26]
WO2017US46480
Priority number, dateUS201662376422P18.08.2016         Original published format: US 201662376422 P
[2019/26]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018034977
Date:22.02.2018
Language:EN
[2018/08]
Type: A1 Application with search report 
No.:EP3500296
Date:26.06.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 22.02.2018 takes the place of the publication of the European patent application.
[2019/26]
Search report(s)International search report - published on:EP22.02.2018
ClassificationIPC:A61K39/395, A61K31/542, C07K16/18, C07D513/04
[2019/26]
CPC:
A61K31/542 (EP); A61K31/546 (US); A61K39/3955 (EP);
A61P25/28 (EP); A61P43/00 (EP); C07D513/04 (EP);
C07K16/18 (EP,US); C07B2200/13 (US); C07K2317/565 (US) (-)
C-Set:
A61K31/542, A61K2300/00 (EP);
A61K39/3955, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/26]
TitleGerman:KOMBINATIONSTHERAPIE MIT BACE-1-INHIBITOR UND ANTI-N3PGLU-ABETA-ANTIKÖRPER[2019/26]
English:COMBINATION THERAPY OF BACE-1 INHIBITOR AND ANTI-N3PGLU ABETA ANTIBODY[2019/26]
French:POLYTHÉRAPIE À BASE D'INHIBITEUR DE BACE-1 ET D'ANTICORPS ANTI-N3PGLU A[2019/26]
Entry into regional phase18.03.2019National basic fee paid 
18.03.2019Designation fee(s) paid 
18.03.2019Examination fee paid 
Examination procedure04.02.2019Amendment by applicant (claims and/or description)
18.03.2019Examination requested  [2019/26]
18.03.2019Date on which the examining division has become responsible
02.12.2019Despatch of communication of loss of particular rights: Claims {1}
12.02.2020Loss of particular rights, legal effect: Claims
02.03.2021Application deemed to be withdrawn, date of legal effect  [2021/31]
30.03.2021Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2021/31]
Fees paidRenewal fee
02.09.2019Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
31.08.202004   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]WO2012098461  (EISAI R&D MAN CO LTD [JP], et al) [A] 1-32 * the whole document *;
 [A]EP2233474  (EISAI R&D MAN CO LTD [JP]) [A] 1-32 * the whole document *;
 [A]WO2012098213  (EISAI R&D MAN CO LTD [JP], et al) [A] 1-32 * the whole document *;
 [A]WO2016043997  (LILLY CO ELI [US]) [A] 1-32 * the whole document *;
 [AP]WO2016137788  (LILLY CO ELI [US]) [AP] 1-32 * claim 1 *
 [A]  - DANIEL OEHLRICH ET AL, "The evolution of amidine-based brain penetrant BACE1 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, AMSTERDAM, NL, (20140501), vol. 24, no. 9, doi:10.1016/j.bmcl.2014.03.025, ISSN 0960-894X, pages 2033 - 2045, XP055233028 [A] 1-32 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2014.03.025
 [A]  - ARUN K. GHOSH ET AL, "BACE1 ([beta]-secretase) inhibitors for the treatment of Alzheimer's disease", CHEMICAL SOCIETY REVIEWS, (20140101), vol. 43, no. 19, doi:10.1039/C3CS60460H, ISSN 0306-0012, pages 6765 - 6813, XP055414773 [A] 1-32 * the whole document *

DOI:   http://dx.doi.org/10.1039/C3CS60460H
by applicantUS8679498
 US8278334
 WO2016043997
    - KABAT et al., Ann. NY Acad. Sci., (19710000), vol. 190, pages 382 - 393
    - NORTH et al., "A New Clustering of Antibody CDR Loop Conformations", Journal of Molecular Biology, (20110000), vol. 406, doi:doi:10.1016/j.jmb.2010.10.030, pages 228 - 256, XP028129711

DOI:   http://dx.doi.org/10.1016/j.jmb.2010.10.030
    - GOULD, P.L., "Salt selection for basic drugs", International Journal of Pharmaceutics, (19860000), vol. 33, doi:doi:10.1016/0378-5173(86)90055-4, pages 201 - 217, XP025813036

DOI:   http://dx.doi.org/10.1016/0378-5173(86)90055-4
    - BASTIN, R.J. et al., "Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities", Org. Proc. Res. Dev., (20000000), vol. 4, no. 5, pages 427 - 435
    - JACS, (19990000), vol. 121, page 8649
    - The United States Pharmacopeia #23, National Formulary #18, (19950000), pages 1843 - 1844
    - VASSAR et al., Science, (19990000), vol. 286, pages 735 - 742
    - YANG, J. Neurochemistry, (20040000), vol. 91, no. 6, pages 1249 - 1259
    - VASSER et al., Science, (19990000), vol. 286, pages 735 - 741
    - MAY et al., Journal ofNeuroscience, (20110000), vol. 31, pages 16507 - 16516
    - ESTERHAZY et al., Cell Metabolism, (20110000), vol. 14, pages 365 - 377
    - JOHNSON-WOOD et al., Proc. Natl. Acad. Sci. USA, (19970000), vol. 94, pages 1550 - 1555
    - GAMES et al., Nature, (19950000), vol. 373, pages 523 - 527
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.